← feed

Is NCT01602406 results overdue?

Yes — results are overdue. Primary completion was 2017-08-02; the FDAAA-801 reporting deadline (2018-08-02) passed 2880 days ago and no results are posted on ClinicalTrials.gov.

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

NCT IDNCT01602406 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-08-02 (ACTUAL)
Reporting deadline2018-08-02 (completion + 365d)
Days overdue2880
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 5d9a1a1a6ff8a59b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01602406. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →